Showing results (171-180 of 312) with videos related to
Sort By:
Pageof 32
The Journal of Allergy and Clinical Immunology|November 12, 2018
Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitisThomas Werfel, Gary Layton, Michael Yeadon, et al.Frontiers in Immunology|June 22, 2026
Staphylococcus aureus serine protease-like protein B elicits a type 1/type 2 immune response in atopic dermatitis patientsRebecca Pospich, Goran Abdurrahman, Tatjana Honstein, et al.Acta Dermato-Venereologica|October 26, 2020
Histamine 2 Receptor Agonism and Histamine 4 Receptor Antagonism Ameliorate Inflammation in a Model of PsoriasisKristine Rossbach, Katharina Wahle, Gustav Bruer, et al.Dermatology and Therapy|May 11, 2022
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic DermatitisMarjolein S de Bruin-Weller, Esther Serra-Baldrich, Sebastien Barbarot, et al.The Journal of Allergy and Clinical Immunology|June 25, 2025
Subclinical inflammation precedes atopic dermatitis relapsesBenjamin Al, Nicholas Holzscheck, Stephan Traidl, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 11, 2016
α-NAC-Specific Autoreactive CD8+ T Cells in Atopic Dermatitis Are of an Effector Memory Type and Secrete IL-4 and IFN-γLennart M Roesner, Annice Heratizadeh, Susanne Wieschowski, et al.Allergologie Select|December 25, 2023
DGAKI and PEI in dialogue 2023: Diagnostics and allergen immunotherapyOliver Pfaar, Eckard Hamelmann, Christian Taube, et al.Allergy|November 24, 2019
Is allergy immunotherapy with birch sufficient to treat patients allergic to pollen of tree species of the birch homologous group?Jörg Kleine-Tebbe, Torsten Zuberbier, Thomas Werfel, et al.The Journal of Dermatological Treatment|March 13, 2023
Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trialJacob P Thyssen, Thomas Werfel, Sebastien Barbarot, et al.Journal of the American Academy of Dermatology|May 9, 2008
A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitisThomas Schwarz, Inga Kreiselmaier, Thomas Bieber, et al.Pageof 32